Middle East & Africa Stem Cell Assay Market

Middle East and Africa Stem Cell Assay Market Size (2024 to 2029)

The Middle East & Africa Stem Cell Assay Market Size is valued at USD 84.67 Million in 2024 and is expected to be growing at a CAGR of 16.3%, reaching USD 180.14 Million by 2029 during the forecast period 2024 to 2029.

Stem cells have a remarkable potential to develop into numerous types of cells and are engaged in the body's internal repair mechanism throughout the Middle East and Africa. In addition, stem cell assays are procedures for testing living cells on factors such as shape, size, and others to assess their biochemical and cellular activity. As a result of these characteristics, stem cell tests are widely used in pharmaceutical development.

During the projected period, the growing biotechnology sector and the rising worldwide burden of diseases like cancer, diabetes, and others are expected to be the primary drivers of market expansion.

The World Health Organization predicted the number of diabetic patients worldwide to be over 422 million in 2014. Furthermore, the World Health Organization predicted that diabetes would be the seventh most significant cause of death in the Middle East and Africa by 2030. Again, increased healthcare expenditures and government backing would propel the market forward during the projection period.

The Middle East and Africa market has expanded significantly due to many successful stem cell therapy cases. In addition, a lot of R&D projects are assisting the market's expansion.

However, constraints such as strict government rules, high procedural costs, and a lack of knowledge and skilled labor would limit market expansion throughout the forecast period.

However, a scarcity of skilled specialists to analyze stem cells, the expensive cost of instruments and stem cell-based therapies, and strict intellectual property rights hamper the market's growth. Nevertheless, during the projection period, the market will develop due to the increased evolution of new technologies and the expansion of the patient pool.

However, stem cells are not correctly differentiated into the requisite adult cell type. In that case, transplanted stem cells may revert to teratomas cells that create teratoma, and transplant rejection is always a possibility. Therefore, the market for stem cell assays is projected to be restrained.

This research report on the Middle East & Africa Stem Cell Assay Market has been segmented and sub-segmented into the following categories.

By Assay Type:

• Cell Viability & Toxicity Assays
• Purification Assays
• Differentiation assays
• function assays
• Identification assays
• proliferation assays
• cell apoptosis assays

By Kits:

• Adult stem cell kits
• Human embryonic stem cell kits

By Application:

• Regenerative Medicine
• Therapy development
• Drug discovery and development
• clinical research

By End User:

• Research institutes
• Industry research

By Country:

• KSA
• UAE
• Israel
• the rest of the GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East and Africa is predicted to rise at a decent CAGR due to expanding awareness and increasing healthcare expenditures in the region.

The acceptance of stem cell assay and the introduction of new technologies are driving up demand for stem cell assay. In addition, the market is growing due to the increase in demand for drug testing and increased research by governmental and private research institutes. Another reason that is propelling the market is the rise in chronic disorders.

The increasing biotechnology sector and sizeable patient population drive the market for stem cell assays in the Middle East and Africa. Furthermore, growing government assistance for research and development helps market growth.

The Kuwait Stem cell assay market is the Middle East's second most generous contributor to biotechnology research and development.

The Saudi Arabia stem cell assay market is expected to grow due to the rising acceptance of new technologies and a large patient population suffering from diabetes, cancer, and others.

The UAE Stem cell assay market contributes to reaching significant growth due to the increased healthcare expenditures and the presence of established economies.

The presence of developed economies such as Saudi Arabia, Kuwait, and Qatar within the area helps the region's market growth with a well-developed healthcare sector and large healthcare expenditures.

KEY MARKET PLAYERS

Promising Companies dominating the Middle East & Africa Stem Cell Assay Market Profiled in the Report are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Cellular Dynamics International Inc., Hemogenix, and Cell Biolabs Inc, GE Healthcare, Bio-Rad Laboratories, Inc, Stem cell Technologies Inc., Merck KGaA, Promega Corporation.